1 year, 5 months ago
via hepatitisanswers.com
What is Boceprevir and how can it help type C hepatitis?
Separate topics with commas, or by pressing return. Use the delete or backspace key to edit or remove existing topics.
You can leave an optional "tip" with Mahalo's virtual currency, Mahalo Dollars. If you are asking a difficult question that might require some research, or if you'd like a wide variety of feedback, a higher tip often leads to more answers to your question.
M$1 Answer
Hello @couponchic!
Boceprivir is a protease inhibitor. This is being studied as a treatment for hepatitis C and being developed by Schering-Plough and absorbed into the Merck's new pipeline since it bought Schering in 2009. As of 2008, it is in the phase II clinical trials.
The Phase 2 study results of Beceprivir were announced at the 44th annual meeting of the European Association for the Study of the Liver in Copenhagen in April 2009. It this is used in combination with peginterferon alfa-2b and ribavirin, boceprivier use will result in higher sustained viral response rate in the most difficult-to-treat patients with genotype 1.
Anemia is the most common side effect of this medicine. It can happen in half of the patients who received boceprivir and by about a 1/3 of the patients taking peginterferon alfa-2b plubs ribavirin at the standard dose. The study was led by Dr. Paul Kwo, associate professor of medicine at the School of Medicine,[Indiana University Indianapolis, Indiana, USA
Boceprivir is a protease inhibitor. This is being studied as a treatment for hepatitis C and being developed by Schering-Plough and absorbed into the Merck's new pipeline since it bought Schering in 2009. As of 2008, it is in the phase II clinical trials.
The Phase 2 study results of Beceprivir were announced at the 44th annual meeting of the European Association for the Study of the Liver in Copenhagen in April 2009. It this is used in combination with peginterferon alfa-2b and ribavirin, boceprivier use will result in higher sustained viral response rate in the most difficult-to-treat patients with genotype 1.
Anemia is the most common side effect of this medicine. It can happen in half of the patients who received boceprivir and by about a 1/3 of the patients taking peginterferon alfa-2b plubs ribavirin at the standard dose. The study was led by Dr. Paul Kwo, associate professor of medicine at the School of Medicine,[Indiana University Indianapolis, Indiana, USA
images:
You can leave an optional "tip" with Mahalo's virtual currency, Mahalo Dollars. If you are asking a difficult question that might require some research, or if you'd like a wide variety of feedback, a higher tip often leads to more answers to your question.
M$Report Abuse
